Status:
COMPLETED
Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Huntington's Disease
Eligibility:
All Genders
26+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical trial is to extend the Pre-Crest study (Protocol # (NCT00592995) to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at...
Detailed Description
Extensive evidence exists that neurodegeneration begins many years before HD can be diagnosed clinically. Therefore, it is most desirable to begin a neuroprotective therapy before or during this prema...
Eligibility Criteria
Inclusion
- Individuals who have completed the Pre-CREST Study.
- Individuals capable of providing independent informed consent and complying with trial procedures.
Exclusion
- Clinical evidence of unstable medical or psychiatric illness in the investigator's judgment.
- Additional eligibility criteria apply.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT01411150
Start Date
May 1 2009
End Date
September 1 2012
Last Update
February 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Charlestown, Massachusetts, United States, 02129